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Abstract
Hypogonadism is probably very common among patients with advanced disease. It may result from the
disease itself but might also be caused or exacerbated by the drugs used to treat these patients and their
symptoms. Opioids are notorious for their ability to depress the production of androgens by both adrenals
and gonads. The corticosteroids used in more than 30% of patients with advanced disease may also contrib-
ute to hypogonadism.  The symptoms of hypogonadism may involve not only fatigue, lack of energy and loss
of libido, but also most probably increased sensitivity to pain. In many cases this may lead to increased doses
of opioids and increased inhibition of androgen production. Opioid-induced hypogonadism may thus con-
tribute to the development of opioid tolerance. Treatment with androgens for these indications is still
controversial and not widely accepted. Androgens may have different adverse effects and their effect on pain
has not yet been confirmed in clinical trials. Many patients (with breast and prostate cancers) may have
hypogonadism induced pharmacologically in order to inhibit tumour growth. Treatment with androgens in
these cases may be contraindicated. Conversely, patients with iatrogenic hypogonadism may suffer more
pain and other symptoms which may negatively influence their quality of life.
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Introduction
A healthy male synthesizes about 5 mg of test-
osterone per 24 hours. Testosterone is converted in
the androgen-sensitive peripheral tissues to the more
active dihydrotestosterone (DHT). These tissues in-
clude the testes, prostate gland, hair follicles and
muscles. Conversion of testosterone to DHT is criti-
cal to the development of external genitalia in boys.
Testosterone is also converted to estradiol and an-
drostenedione in adipose tissue. When androstene-
dione is formed in adipose tissue, it may be con-
verted to a form of estrogen called estrone.
In men, 95% of circulating testosterone is syn-
thesized in the testes, 5% in the adrenals. Only 20%
of DHT comes from the testes, while 80% comes
from conversion in the peripheral tissues facilitated
by 5-a-reductase. In women, approximately half the
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androgens are produced in the adrenals and ova-
ries and the other half come from the peripheral
conversion from androstendione and dehydroan-
drostendione. Androstendione is the precursor of
dehydroepiandrosterone (DHEA), which is the main
androgen in women and is produced mainly in the
adrenals. DHEA is a weak androgen and most of it
is found in plasma as sulphate. In women, 20% of
the testosterone in circulation is produced in the
adrenals.
An important factor that determines the trans-
port, metabolism and activity of testosterone is a
protein produced in the liver, the sex hormone-bind-
ing globulin (SHBG). This protein binds approximate-
ly half of the available testosterone, DHT and estra-
diol; the remaining hormones are bound to the al-
bumins. A free fraction of testosterone (1–2% of
the total) is biologically active. All processes that
influence the level of SHBG also play a part in the
activity of testosterone. Neither DHEA-S nor andros-
tendione bind to SHBG.
Hypogonadism
Hypogonadism or hypoandrogenism in men can
be primary, due to testicular insufficiency, or sec-
ondary, due to inhibition of the hypophyseal gona-
dotrophic hormones FSH and LH. In the case of pri-
mary hypogonadism, the gonadotrophins are usu-
ally increased (hypergonadotrophic hypogonadism);
while in the secondary condition the levels of gona-
dotrophins are usually decreased (hypogona-
dotrophic hypogonadism). This latter condition is
the subject of this mini review, as it is a significant
factor contributing to the poor well-being of pa-
tients with advanced disease.
Hypogonadism in men (both primary and sec-
ondary) is defined as a low total testosterone level
in combination with typical symptoms such as fa-
tigue, loss of motivation and confidence, irritabili-
ty, reduced libido and erectile strength and, most
probably, increased sensitivity to pain. The cut-off
value of testosterone characteristic for hypogo-
nadism in men is defined as 8 nmol/L. Although
total testosterone is a good predictor for hypogo-
nadism, it is still unclear which fraction of test-
osterone is biologically active in the ageing popu-
lation. Endocrinologists are used to determining
both free and bound testosterone as well as the
levels of SHBG.
Hypogonadism may result in osteoporosis with
increased risk of fractures, decreased muscle
strength and risk of falls. Testosterone is beneficial
for the functioning of the brain and the immune
system. The “normal” variant of hypogonadism, re-
lated to age, is defined as late-onset hypogonadism.
Studies in large populations show a marked de-
crease of testosterone levels with age in men [1].
The incidence of late-onset hypogonadism in men
aged between 50–79 is at least 8.4% [2]. Low levels
of testosterone are associated with increased mor-
bidity and mortality due to many different condi-
tions, including cardiovascular diseases, diabetes
and cancer [3]. Because late-onset hypogonadism
affects only part of the population, the term andro-
pause is misleading and should not be used. There
is wide discussion as to whether testosterone sub-
stitution in this population is beneficial for the qual-
ity and length of life or not.
Hypogonadism in patients
with advanced disease
Against this “normal” background of hypogo-
nadism present in 8% of the ageing male popula-
tion, clinicians should recognize the secondary forms
of this condition. These may be related to the dis-
eases and the use of different drugs. Many central-
ly-acting drugs may cause hypogonadism, mainly
through inhibition of the hyphyseal-gonadal axis.
Among the drugs with these properties are some
which are very relevant to palliative care: opioids
[4–6], corticosteroids [7] and gabapentin [8]. Can-
cer chemotherapy is also frequently related to de-
creased gonadal function [9–12]. Furthermore, zinc
deficiency may be another risk factor for the devel-
opment of hypogonadism in advanced disease [13].
The prevalence of hypogonadism is higher in
obese patients, those with Type 2 diabetes, coro-
nary heart disease, chronic obstructive lung disease
and various autoimmune diseases [14]. While opio-
ids and hypogonadism induced by opioids and gaba-
pentin are associated with weight gain and obesity,
naltrexone, an opioid antagonist, usually causes
decrease in appetite and weight loss [15, 16]. Low
levels of testosterone may be related to another
symptom common in advanced disease, namely
nausea and vomiting. Women who vomit in early
pregnancy have much lower levels of testosterone
than their non-vomiting controls [17].
Hypoandrogenism in women is much more dif-
ficult to diagnose. In women, it seems that it is not
the absolute values of androgens but the dynamics
of their change that contribute to the symptoms.
Levels of LH are certainly less important for the di-
agnosis than in men. Conversely, a diagnosis of hypo-
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estrogenism in women is simple and is based on
the levels of estradiol and FSH.
Androgens and pain
The influence of androgens on pain threshold
has been suspected for many years [18–20]. Hypog-
onadism in laboratory animals was associated with
decreased pain thresholds and increased pain sen-
sitivity. In humans, however, these relationships are
more controversial. In men, low levels of testoster-
one are certainly associated with increased pain sen-
sitivity. However, women with lower levels of test-
osterone also have reduced pain thresholds [21] but
the relationship is more complex and it is too sim-
ple to state that androgens are the only factor re-
sponsible for pain modulation.
Opioids may depress androgen levels
Hypogonadism was first noticed in patients who
had been using methadone for a long time [22] but
this condition was later confirmed for many other,
if not all, opioids [4, 23, 24]. The effect is seen in
patients receiving opioids via different routes, in-
trathecal [6] as well as systemic [4, 5, 25, 26]. It
seems probable that buprenorphine causes less go-
nadal suppression than the other opioids [24, 27].
Opioids inhibit the release of hypophyseal go-
nadotrophins, thus opioid-induced  hypogonadism
can be best described as hypogonadotrophic hy-
pogonadism. The hypogonadotrophic effect of opi-
oids can be observed even after the administration
of a single opioid dose, both in laboratory animals
[28] and in humans. While the gonadotrophins are
depressed by opioids, hypophysis may secrete more
prolactin under the same circumstances [29]. Pyri-
doxine may counteract this effect [30]. Opioid-in-
duced hyperprolactinaemia may occasionally cause
painful swelling of the nipples and galactorrhoea
[31].
Depression of the hypophysis is not limited to
the gonadotrophins alone. Opioids may also inhibit
ACTH release [32] and in such a way cause adrenal
hypofunction. This effect may be even more pro-
nounced when the patient receives steroids.
The relationship between
hypogonadism and sensitivity to pain
Hypogonadism induces several generic symp-
toms (such as fatigue, weakness and irritability)
which may also be caused by other multiple factors.
Potentially, administration of testosterone may be
beneficial to fatigued cancer and HIV patients but
large clinical trials have not yet been completed
[33–35]. Of more interest is the relationship be-
tween hypogonadism and increased sensitivity to
pain. This relationship is very well defined in labora-
tory animals [18–20, 36, 37] but can only be detect-
ed in humans indirectly. Men have higher thresh-
olds for cold-induced pain than women [38]. There
are no studies supporting the idea that testoster-
one therapy may assist pain treatment. However,
we recently published a case series suggesting that
in many cases of pain which is difficult to treat, the
addition of testosterone may be beneficial (Roantree,
Zylicz, Adv. Pall. Med. 2009; 8: 69–74 — this issue).
Does DHEA play an important role
in the symptoms of hypogonadism?
Dehydroepiandrosterone (DHEA) and its sulphate
esters (DHEA-S) are the most abundant androgens
in the circulation, DHEA and DHEA-S playing an es-
pecially important role for women. However, the
androgen effect of these steroids is weak. The levels
of DHEA are depressed in hypogonadism alongside
testosterone, but the evidence for the long-term
benefit of DHEA replacement, alone or in combina-
tion with testosterone in hypogonadism, is lacking
[39]. Opioids may depress both testosterone corti-
costeroids and DHEA [40].
Which preparation of testosterone
to use?
As opioids are responsible for hypogonadism and
testosterone replacement, either using or not using
DHEA-S has the potential to improve pain control
one should notice that there are several snags. An-
drogens may be tried and occasionally produce more
effective pain control and improved quality of life.
Testosterone should be applied as a transdermal
patch, as it is not only simple to start but also easy to
discontinue in the case of adverse effects. Transder-
mal testosterone may be effective within 24–48 hours,
although it usually takes weeks of substitution to
increase the plasma levels of this hormone. Blood
levels of DHEA-S increase much more rapidly. It looks
as if testosterone has the potential to increase not
only the efficacy but also the toxicity of opioids
(Roantree, Zylicz, Adv. Pall. Med. 2009; 8: 69–74 —
this issue). This is the reason why the slow release
preparations injected intramuscularly are initially con-
traindicated. Transdermal patches can be replaced
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by a transdermal gel preparation when higher doses
are needed. Oral tablets containing testosterone can
be prescribed, although they are stigmatized by a
higher probability of liver toxicity [41].
Contraindications for testosterone
therapy
Despite (potential) benefits of therapy with an-
drogens, there are also several contraindications.
Obviously, patients suffering from prostate cancer,
and deliberately deprived of androgens in order to
halt tumour growth and invasion, should not be
treated with androgens. Similarly, patients with
breast cancer should avoid androgens as a propor-
tion of them may be metabolized to estrogens and
hence stimulate tumour growth. Other contraindi-
cations are relative. Hypogonadism in males is as-
sociated with an enhancement of fibrinolytic inhibi-
tion via increased synthesis of the plasminogen ac-
tivator inhibitor PAI-1 [42]. Androgens may have
profibrinolytic effects. Patients with high and toxic
doses of opioids should avoid androgens as they
may further increase toxicity. The dose of opioids
should be decreased before starting a patient on
androgens. Testosterone may increase sensitivity to
insulin in diabetic patients [43] and in such a way
induce dangerous hypoglycaemia.
In young males, testosterone can be used in su-
praphysiologic doses, while in older men the doses
should be limited to substitution only. In females,
androgens may cause unpleasant skin reactions
(acne) and liver function changes, as well as hirsuit-
ism and masculinization. It seems probable that in
women testosterone should be used together with
hormone replacement therapy (HRT). Combinations
of oestrogens and methyltestosterone are available
on the market.
Do patients with androgen deprivation
experience more pain?
The treatment of hormone-responsive prostate
cancer is based on androgen deprivation, either
through treatment with hormones that inhibit the
release of gonadotrophins from the hypophysis,
blocking synthesis of androgens, or through pro-
viding blockers of the androgen receptors. Treat-
ment with corticosteroids is also seen as beneficial
for prostate cancer, as it further decreases the adre-
nal synthesis of androgens [7]. This deprivation, in
the light of the facts discussed above, may contrib-
ute to decreased pain thresholds and more com-
plaints of pain. To my knowledge, there are no data
to confirm the anecdotes that those with prostate
cancer consume more opioids for their pain or ex-
perience greater discomfort than other patients. In
my own pain practice, I am interested in the pain
induced by the compression of small cutaneous
nerves against bony prominences. This kind of pain
is usually overlooked and can easily be treated with
local depo-steroid injections (Zylicz et al, 2009, in
press). Most of the patients seeking this kind of
treatment in my practice are patients with prostate
cancer.
Does testosterone therapy increase
the risk of prostate cancer?
Therapy with androgens is continuously ques-
tioned, especially with regard to the risk of prostate
cancer. Long-term studies have failed to provide a
definitive answer to this question.  An in-depth anal-
ysis of 18 studies found no association between
testosterone blood levels and risk of prostate can-
cer [44]. As many older patients may harbour clini-
cally silent prostate cancers, an increase in andro-
gen substitution may still potentially be detrimen-
tal to them.
Hypogonadism in itch of cholestasis
Pruritus of cholestasis is no longer thought (only)
to be associated with the accumulation of bile acids
[45]. Instead, there is ample evidence that a chole-
static liver produces large amounts of endogenous
opioids [46], which may depress levels of  testoster-
one and DHEA-S and induce hypogonadism. Low
levels of androgens may sensitize the spinal cord
and facilitate itch. There are some old anecdotal data
suggesting that testosterone may be beneficial in
the treatment of cholestatic pruritus [47, 48]. This
therapy did not become popular, as testosterone also
has the potential to increase the cholestasis.
Conclusion
Testosterone and other androgens may play an
important role in the well-being of patients with
advanced disease. Substitution of these hormones
may, potentially, improve a patient's quality of life
and increase the pain threshold. Evidence for this
effect is still lacking and clinical trials are needed to
confirm case reports. Hypogonadism may be the
key to understanding opioid insensitivity and tole-
rance.
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